TDD AD Pipeline Watch: Aldeyra’s ADX‑629 Performs Well in Phase 2 Study
Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. Aldeyra expects to initiate a multicenter, randomized, placebo-controlled Phase 1/2 clinical trial of ADX‑246 in healthy volunteers and patients with AD in the first half of 2024. Topline results from the trial […]